Updated:
HealthQuad
HealthQuad was launched in New Delhi as a dedicated healthcare private equity fund, one of the few Indian firms constructed exclusively around...
HealthQuad
HealthQuad was launched in New Delhi as a dedicated healthcare private equity fund, one of the few Indian firms constructed exclusively around health-sector innovation. Co-founders Abrar Mir and Ajay Mahipal designed the vehicle to span early-stage venture and growth equity, acknowledging that Indian healthcare requires both clinic-level operational expertise and the risk appetite to back pre-revenue device makers. The firm has historically raised capital from development finance institutions and European family offices seeking targeted exposure to India's under-penetrated health markets. HealthQuad's strategy blends direct equity investments in healthcare delivery businesses with strategic bets on health-tech enablers. The firm positions itself across sub-sectors including single-specialty hospital chains, diagnostic-lab networks, medical device manufacturing, and digital health platforms. Confirmed portfolio companies include Asian Institute of Nephrology and Urology, a multi-city urology-focused hospital group, and RED.Health, a medical emergency-response platform that coordinates ambulance networks across major Indian metros. The firm selectively backs seed-stage health-tech ventures but concentrates the majority of its deployment on growth-stage businesses already generating revenue in Tier-1 and Tier-2 cities. The fund operates from a single office in New Delhi with a lean investment team, though specific headcount has not been publicly disclosed. HealthQuad closed its second fund — HealthQuad Fund II — with reported commitments near $100 million, attracting backing from institutions including the UK's CDC Group (per Infrastructure Investor, 2020). The firm has not publicized a third fund close or total AUM, which is characteristic of India-based mid-market managers that raise capital predominantly from DFIs and select family offices rather than through broad institutional syndication. HealthQuad's structural distinction lies in its singular sector mandate at a time when most India-focused PE firms operate generalist buyout or multi-sector venture strategies. The firm's blend of aid-linked limited partners and commercial healthcare investments creates a fund dynamic uncommon in Asian private markets — one that permits longer hold periods for hospital assets while still targeting market-rate returns. This unusual LP base, combined with a pipeline sourced from India's fragmented single-specialty hospital market, gives HealthQuad an origination advantage that broad-scope competitors cannot easily replicate.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
India
City
New Delhi
Corporate office
New Delhi, India
Principals
Abrar Mir
Co-Founder & Managing Partner
Ajay Mahipal
Co-Founder & Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at HealthQuad?
Co-founders Abrar Mir and Ajay Mahipal serve as Managing Partners and lead the firm's investment committee. Both have backgrounds in Indian private equity and healthcare advisory, though the firm does not publicly detail the specific split of investment-committee authority between them. In practice, mid-market India funds of HealthQuad's size typically operate with a flat decision-making structure where both partners must approve any new commitment.
Is HealthQuad a single family office or an institutional fund manager?
HealthQuad is an institutional private equity fund manager, not a family office. It raises capital from external limited partners — primarily development finance institutions and European family offices — rather than managing the wealth of a single family. Its legal structure is a Sebi-registered alternative investment fund under Indian securities regulations.
What investment stages does HealthQuad target?
HealthQuad invests across early-stage venture, growth equity, and structured minority positions, though the majority of its deployment targets growth-stage companies with established revenue. The firm is willing to back pre-revenue medical device and health-tech startups from a seed-stage allocation, but its core check size and portfolio construction favor businesses that have already achieved clinical or operational scale in Indian Tier-1 and Tier-2 cities.
Which healthcare sub-sectors does HealthQuad explicitly avoid?
HealthQuad has not published a formal exclusions list, but its investment record suggests it avoids pharmaceutical drug discovery and large-scale hospital greenfield projects — two capital-intensive sub-sectors that demand timelines and risk profiles inconsistent with a mid-market private equity fund structure. The firm has also not disclosed any investments in health insurance or payer-side businesses.
How does HealthQuad source its deals?
HealthQuad relies on a proprietary network within India's single-specialty hospital and diagnostic-chain ecosystem — a fragmented market where most providers are founder-owned and do not transact through broad auction processes. The firm's narrow sector focus and development-finance LP relationships also generate inbound referrals from other impact-oriented investors and multilateral agencies active in Indian healthcare infrastructure.
Does HealthQuad participate in fund commitments or only direct deals?
HealthQuad exclusively makes direct investments in operating healthcare companies and health-tech platforms. The firm does not operate a fund-of-funds program, nor has it disclosed any LP commitments to other private equity or venture capital vehicles. Its mandate is to deploy capital into portfolio companies where the investment team can take board seats and influence operational direction.
Is HealthQuad related to any other investment firm or conglomerate?
There is no public record of HealthQuad being a subsidiary of, or affiliated with, a larger financial services group, hospital network, or industrial conglomerate. The firm appears to be an independent partnership launched by Mir and Mahipal, though the absence of detailed corporate filings makes complete independence difficult to confirm definitively.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: